Effects of combined treatment with CD25- and CD154-specific monoclonal antibodies in non-human primate allotransplantation.


Journal Article

The CD154-specific monoclonal antibody (Mab) hu5c8 greatly prolongs allograft survival in primates. The CD25-specific Mab daclizumab has not, to date, been paired with hu5c8. We evaluated the effects of hu5c8 in vitro, alone and in combination with daclizumab on rhesus-mixed lymphocyte reactions (MLRs). We then evaluated therapy with hu5c8 and daclizumab in four monkey renal allograft recipients compared with monkeys untreated or contemporaneously treated with hu5c8 alone. Lymphocyte proliferation in MLR was reduced by both daclizumab and hu5c8, and their combined effects were additive. Rejection-free allograft survival in monkeys treated with both hu5c8 and daclizumab (74-479 days) was not significantly better than animals treated with hu5c8 alone (257-587 days), and one combined therapy animal rejected while still on hu5c8 therapy, a condition not typically seen with hu5c8 monotherapy. Although daclizumab and hu5c8 are additively effective in MLR, they do not appear to be synergistic in vivo in rhesus monkeys.

Full Text

Duke Authors

Cited Authors

  • Xu, H; Elster, EA; Blair, PJ; Burkly, LC; Tadaki, DK; Harlan, DM; Kirk, AD

Published Date

  • November 2003

Published In

Volume / Issue

  • 3 / 11

Start / End Page

  • 1350 - 1354

PubMed ID

  • 14525594

Pubmed Central ID

  • 14525594

International Standard Serial Number (ISSN)

  • 1600-6135

Digital Object Identifier (DOI)

  • 10.1046/j.1600-6135.2003.00235.x


  • eng

Conference Location

  • United States